This work is licensed under a Creative Commons Attribution 4.0 International License.
B2
General Information
DRACP ID DRACP00715
Peptide Name B2
Sequence KKLFKKILKYLKK
Sequence Length 13
UniProt ID Not available
PubChem CID Not available
Origin antimicrobial peptides
Type Synthetic peptide
Classification
Active ACP
Activity Information
| Cell Line | Disease | Cancer Classified | Activity | Assay | Testing Time | Literature |
|---|---|---|---|---|---|---|
| MCF-7 | Invasive breast carcinoma of no special type | Carcinoma | IC50=30.8±3.4 μM | MTT assay | 48h | 1 |
| MCF-7/ADM | Invasive breast carcinoma of no special type | Carcinoma | IC50=36.1±6.7 μM | MTT assay | 48h | 1 |
| K562 | Blast phase chronic myelogenous leukemia, BCR-ABL1 positive; Chronic myeloid leukemia | Leukemia | IC50=33.6±4.2 μM | MTT assay | 48h | 1 |
| K562/Adr | Blast phase chronic myelogenous leukemia; Chronic myeloid leukemia | Leukemia | IC50=39.6±5.7 μM | MTT assay | 48h | 1 |
Hemolytic Activity Rabbit red blood cells: very low hemolytic activity even at the concentration of 160 μm(as show in fig.3)
Normal (non-cancerous) Cytotoxicity GES-1: IC50=89.6±7.2 μM
Target Not available
Affinity Not available
Mechanism disrupt the cell membrane, trigger the cytochrome C release into cytoplasm, and ultimately lead to apoptosis
Nature Anticancer; Antitumor; Antimicrobial
Structure Information
Helicity Not available
Linear/Cyclic Linear
Disulfide/Other Bond Not available
N-terminal Modification Free
C-terminal Modification Free
Other Modification None
Chiral L
Physicochemical Information
Formula C84H148N20O15
Absent amino acids ACDEGHMNPQRSTVW
Common amino acids K
Mass 189245
Pl 11.22
Basic residues 7
Acidic residues 0
Hydrophobic residues 5
Net charge 7
Boman Index -1633
Hydrophobicity -76.15
Aliphatic Index 120
Half Life
Mammalian: 1.3 hour
Yeast: 3 min
E.coli: 2 min
Extinction Coefficient cystines 1490
Absorbance 280nm 124.17
Polar residues 1
Amino acid distribution
Literature Information
Literature 1
Pubmed ID 28524273
Title Synthesis and biological evaluation of novel peptides based on antimicrobial peptides as potential agents with antitumor and multidrug resistance-reversing activities
Year 2017
Patent
Patent ID Not available
Patent Title Not available
Other Iinformation Not available
Other Published ID Not available
This work is licensed under a Creative Commons Attribution 4.0 International License.